Slots: 1
Deadlines
Internal Deadline: Friday, December 6th, 2024, 5pm PT Contact RII.
LOI: January 24, 2025
External Deadline: February 24, 2025
Award Information
Award Type: Cooperative Agreement
Estimated Number of Awards: 32-40
Anticipated Award Amount: Application budgets are limited to no more than $1.7 million in direct costs per year.
Who May Serve as PI: The named PDs/PIs for applications for NCTN Network Lead Academic Participating Sites cannot be named as PDs/PIs on applications for:
- NCTN – Network Group Operations Centers (RFA-CA-24-030)
- NCTN – Network Group Statistical and Data Management Centers (RFA-CA-24-031)
- NCTN – Canadian Collaborating Clinical Trials Network (RFA-CA-24-032)
- NCTN – Network Radiotherapy and Imaging Core Services Center (RFA-CA-24-034)
However, an individual who is designated as a PD/PI on the application for the NCTN Network Lead Academic Participating Site can, if appropriate, be listed as key personnel on applications for any of the RFAs listed above.
Link to Award: https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-033.html
Process for Limited Submissions
PIs must submit their application as a Limited Submission through the Research Initiatives and Infrastructure (RII) Application Portal: https://rii.usc.edu/oor-portal/. Use the template provided here: RII Limited Submission Applicant Template
Materials to submit include:
- (1) Two-Page Proposal Summary (1” margins; single-spaced; standard font type, e.g. Arial, Helvetica, Times New Roman, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 2-page limit will be excluded from review. You must use the template linked above.
- (2) CV – (5 pages maximum)
Note: The portal requires information about the PIs in addition to department and contact information, including the 10-digit USC ID#. Please have this material prepared before beginning this application.
Purpose
This Notice of Funding Opportunity Announcement (NOFO) is one of six NOFOs that support the comprehensive effort by the National Cancer Institute (NCI) to provide the infrastructure for the conduct of national clinical trials through the National Clinical Trials Network (NCTN). The primary goal of the NCTN is the conduct of multi-center, late-phase, clinical treatment trials (i.e., randomized phase 2 and phase 3 trials) and advanced imaging trials across a broad range of cancers, modalities, and diverse patient populations as part of the NCI’s overall clinical research program for adults, adolescents and young adults, and children with cancer. The NCTN also conducts, as necessary, preliminary studies needed for development of definitive trials, especially umbrella/basket trials and rare tumor trials, when an extensive, national patient catchment area is required.
The NCTN Program supports the following clinical trials infrastructure components through individual awards made under the respective NOFOs indicated below:
- NCTN – Network Group Operations Centers under RFA-CA-24-030 (U10)
- NCTN – Network Group Statistics and Data Management Centers under RFA-CA-24-031 (U10)
- NCTN – Canadian Collaborating Clinical Trials Network under RFA-CA-24-032 (U10)
- NCTN – Network Lead Academic Participating Sites under RFA-CA-24-033 (UG1) – this NOFO
- NCTN – Network Radiotherapy & Imaging Core Services Center under RFA-CA-24-034 (U24)
- NCTN – Network Group Integrated Translational Science Centers under RFA-CA-24-035 (UG1)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Network Lead Academic Participating Sites (LAPS) for the NCI National Clinical Trials Network (NCTN). The NCTN Network LAPS will provide scientific leadership by helping to develop and conduct clinical trials in association with one or more adult U.S. Network Groups and will contribute substantial accrual to clinical trials conducted across the entire NCTN.
Visit our Institutionally Limited Submission webpage for more updates and other announcements.